Pentavalent

Bengaluru, India Founded: 2015 • Age: 11 yrs
Vaccines and research services for infectious diseases are provided.

About Pentavalent

Pentavalent is a Healthcare company based in Bengaluru (India) founded in 2015 by Bhavani PV and Soumya Paul. Vaccines and research services for infectious diseases are provided. Pentavalent has raised $40.82 thousand across 2 funding rounds from investors including Bioinnovation Centre and Startup Karnataka. Pentavalent was last valued at $806.3 thousand in October 2020. Its Indian entity Pentavalent Bio Sciences Private Limited reported revenue of β‚Ή2.01 Cr. Pentavalent offers products and services including Antibodies, Antigens, Cytokines, and Enzymes. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Prophylactic.

Company details

Pentavalent was founded in 2015 in Bengaluru, India, within the biotechnology sector. Research services are delivered in proteomics, genomics, molecular techniques, antibody generation, microbial studies, cell culture, computational assistance, and preclinical areas. Vaccines and diagnostics for infectious diseases are developed as part of core operations.

  • Headquarters Bengaluru, India
  • Founders Bhavani PV, Soumya Paul
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website pentavalent.in
  • Social LinkedIn
  • Legal Name Pentavalent Bio Sciences Private Limited
  • Date of Incorporation 24 Feb, 2015
  • Jurisdiction Bangalore, Karnataka, India
Key Metrics
  • Annual Revenue
    ₹2.01 Cr

    FY 2023 · +356% YoY

  • Net Profit
    ₹17.2 Lakh

    FY 2023 · 9% margin

  • EBITDA
    ₹25.8 Lakh

    FY 2023 · 13% margin

  • Total Equity Funding
    $40.82K (USD)

    in 2 rounds

  • Latest Funding Round
    $40.82K (USD), Seed

    Oct 2020

  • Investors

Products & Services of Pentavalent

Pentavalent offers a comprehensive portfolio of products and services, including Antibodies, Antigens, Cytokines, and Enzymes.

Antibodies
Diagnostic Reagents

Monoclonal antibodies for precise IVD testing applications

Antigens
Diagnostic Reagents

Recombinant proteins tailored for diagnostics and research

Cytokines
Biochemicals

Signaling proteins for immune response diagnostics

Enzymes
Biochemicals

Purified enzymes for IVD and health applications

Funding Insights of Pentavalent

Pentavalent has successfully raised a total of $40.82K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $40.82 thousand completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $40,819
  • Total Rounds 2
  • Last Round Seed β€” $40,819
  • First Round $77,200

    (May 2017)

  • Investors Count 2

All 2 funding rounds of Pentavalent with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2020$40,819Seed$806,301Bioinnovation Centre
–
May 2017$77,200Grant––
Valuation history

Last known valuation $806,301 (Oct 2020). 2 investors in total: 2 institutional.

Investors in Pentavalent

Pentavalent has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Bioinnovation Centre and Startup Karnataka.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Govt backed startup incubator focused on the Life Science sector
2015bioinnovationcentre.comBengaluru, India
Support for startups in Karnataka is delivered through policies, funding, and networking services.
2004missionstartupkarnataka.orgBengaluru, India
Premium access

Investor details for Pentavalent

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Pentavalent Bio Sciences Private Limited (Pentavalent)

Pentavalent Bio Sciences Private Limited is the primary company behind Pentavalent. The board of Pentavalent Bio Sciences Private Limited currently have 2 directors; the longest-serving is Soumya Paul, appointed in 2015. 3 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Soumya Paul
DIN 07070580
Director24 Feb 201511 yrs 8 moPentavalent Bio Sciences Private Limited
Murali Shripathy Harishchandra
DIN 07396173
Director04 Dec 201510 yrs 11 moPentavalent Bio Sciences Private Limited

People of Pentavalent

2 people are tracked at Pentavalent (2 in leadership).

NameRoleGroup
Bhavani PV
Co-Founder & DirectorLeadership
Co-Founder & DirectorLeadership
Premium access

Complete people profiles for Pentavalent

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Pentavalent

Figures of Pentavalent Bio Sciences Private Limited, the primary company behind Pentavalent, for FY 2023. Revenue was ₹2.01 Cr (+356% year on year). Net profit was ₹17.2 Lakh (9% margin). EBITDA was ₹25.8 Lakh (13% margin). Revenue has grown at a compounded annual rate of +88% over three years and +49% over five years.

  • ₹2.01 CrRevenue · FY 2023 · +356% YoY
  • ₹17.2 LakhNet profit · 9% margin
  • ₹25.8 LakhEBITDA · 13% margin
  • ₹18.1 LakhPaid-up capital
  • +88%Revenue CAGR, 3 years
  • +49%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Pentavalent Bio Sciences Private Limited are on its company page.

Premium access

Detailed financial statements for Pentavalent

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Pentavalent

3 dated milestones of Pentavalent across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Pentavalent is founded.
  2. Funding First funding round of $77K.
  3. Funding Latest funding round, Seed, of $41K.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Pentavalent

Pentavalent was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Pentavalent is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Pentavalent is a funded company, having raised a total of $40.82K across 2 funding rounds to date. The company's 1st funding round was a Grant of $77.2K, raised on May 2017.

The primary company behind Pentavalent, Pentavalent Bio Sciences Private Limited, reported revenue of β‚Ή2.01 Cr for FY 2023, up 356% year on year.

Pentavalent was founded in 2015 in Bengaluru, India, within the biotechnology sector. Research services are delivered in proteomics, genomics, molecular techniques, antibody generation, microbial studies, cell culture, computational assistance, and preclinical areas. Vaccines and diagnostics for infectious diseases are developed as part of core operations.

Pentavalent offers Antibodies, Antigens, Cytokines, and Enzymes.

Pentavalent has 2 investors. Key investors include Bioinnovation Centre, and Startup Karnataka.

The valuation of Pentavalent is $806.3K as of Oct 2020.

Pentavalent operates through Pentavalent Bio Sciences Private Limited.

The legal entities of Pentavalent currently have 2 directors, including Soumya Paul, Murali Shripathy Harishchandra.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available